Endoscopic Submucosal Dissection in North America: A Large Prospective Multicenter Study

Peter V. Draganov*, Hiroyuki Aihara, Michael S. Karasik, Saowanee Ngamruengphong, Abdul Aziz Aadam, Mohamed O. Othman, Neil Sharma, Ian S. Grimm, Alaa Rostom, B. Joseph Elmunzer, Salmaan A. Jawaid, Donevan Westerveld, Yaseen B. Perbtani, Brenda J. Hoffman, Alexander Schlachterman, Amanda Siegel, Roxana M. Coman, Andrew Y. Wang, Dennis Yang

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

39 Scopus citations


Background and Aims: Endoscopic submucosal dissection (ESD) in Asia has been shown to be superior to endoscopic mucosal resection (EMR) and surgery for the management of selected early gastrointestinal cancers. We aimed to evaluate technical outcomes of ESD in North America. Methods: We conducted a multicenter prospective study on ESD across 10 centers in the United States and Canada between April 2016 and April 2020. End points included rates of en bloc resection, R0 resection, curative resection, adverse events, factors associated with failed resection, and recurrence post-R0 resection. Results: Six hundred and ninety-two patients (median age, 66 years; 57.8% were men) underwent ESD (median lesion size, 40 mm; interquartile range, 25–52 mm) for lesions in the esophagus (n = 181), stomach (n = 101), duodenum (n = 11), colon (n = 211) and rectum (n = 188). En bloc, R0, and curative resection rates were 91.5%, 84.2%, and 78.3%, respectively. Bleeding and perforation were reported in 2.3% and 2.9% of the cases, respectively. Only 1 patient (0.14%) required surgery for adverse events. On multivariable analysis, severe submucosal fibrosis was associated with failed en bloc, R0, and curative resection and higher risk for adverse events. Overall recurrence was 5.8% (31 of 532) at a mean follow-up of 13.3 months (range, 1–60 months). Conclusions: In this large multicenter prospective North American experience, we demonstrate that ESD can be performed safely, effectively, and is associated with a low recurrence rate. The technical resection outcomes achieved in this study are in line with the current established consensus quality parameters and further support the implementation of ESD for the treatment of select gastrointestinal neoplasms; ClinicalTrials.gov, Number: NCT02989818.

Original languageEnglish (US)
Pages (from-to)2317-2327.e2
Issue number7
StatePublished - Jun 2021


  • EMR
  • Endoscopic Mucosal Resection
  • Endoscopic Submucosal Dissection
  • Gastrointestinal Neoplasms
  • Polyps

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology


Dive into the research topics of 'Endoscopic Submucosal Dissection in North America: A Large Prospective Multicenter Study'. Together they form a unique fingerprint.

Cite this